Results 201 to 210 of about 4,232,654 (389)

Potent and Long‐Lasting Immunogenicity Generated by LNP‐mRNA gE Antigen Against Varicella Zoster Virus via an AI‐Assisted Pipeline

open access: yesAdvanced Science, EarlyView.
This study designs a novel mRNA‐LNP vaccine targeting VZV glycoprotein E (gE) for herpes zoster via an AI‐assisted pipeline. Validated in mice and rhesus macaques, the mRNA‐LNP vaccine shows strong humoral and cellular immune responses, with CD4+ T‐cell responses more effective and durable than Shingrix, offering a promising prophylactic option ...
Kai Dong   +6 more
wiley   +1 more source

Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome

open access: yesAdvanced Science, EarlyView.
Pharmacological SUMOylation inhibition (SUMOi) counteracts tumor immune evasion by unmasking an immunogenic HLA‐I peptide and neoepitope repertoire. By restoring HLA‐I ligand availability through increased antigen processing and presentation, enhanced proteasomal cleavage, and modulated TAP1 peptide affinity, SUMOi boosts tumor immunogenicity ...
Uta M. Demel   +19 more
wiley   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

open access: yesAdvanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang   +10 more
wiley   +1 more source

High-throughput screens identify genotype-specific therapeutics for channelopathies. [PDF]

open access: yesJCI Insight
Egly CL   +9 more
europepmc   +1 more source

Nanoparticle Adjuvant Design Enhances Germinal Center Responses Targeting Conserved Subdominant Epitopes for Pan‐Coronavirus Vaccine Development

open access: yesAdvanced Science, EarlyView.
Current SARS‐CoV‐2 vaccines generate short‐lived, strain‐specific immunity. A polymeric TLR7 agonist nanoparticle (TLR7‐NP) adjuvant enhances lymph node targeting and promotes early and sustained germinal center responses toward conserved S2 epitopes of the spike protein.
Sijin Huang   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy